Your browser doesn't support javascript.
loading
Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target.
Verrier, Eloi R; Ligat, Gaëtan; Heydmann, Laura; Doernbrack, Katharina; Miller, Julija; Maglott-Roth, Anne; Jühling, Frank; El Saghire, Houssein; Heuschkel, Margaux J; Fujiwara, Naoto; Hsieh, Sen-Yung; Hoshida, Yujin; Root, David E; Felli, Emanuele; Pessaux, Patrick; Mukherji, Atish; Mailly, Laurent; Schuster, Catherine; Brino, Laurent; Nassal, Michael; Baumert, Thomas F.
Afiliación
  • Verrier ER; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France Thomas.Baumert@unistra.fr e.verrier@unistra.fr michael.nassal@uniklinik-freiburg.de.
  • Ligat G; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Heydmann L; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Doernbrack K; Department of Internal Medicine II/Molecular Biology, University Hospital Freiburg, Freiburg, Germany.
  • Miller J; Department of Internal Medicine II/Molecular Biology, University Hospital Freiburg, Freiburg, Germany.
  • Maglott-Roth A; IGBMC, Plateforme de Criblage Haut-débit, Illkirch, France.
  • Jühling F; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • El Saghire H; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Heuschkel MJ; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Fujiwara N; Department of Internal Medicine, Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Hsieh SY; Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Hoshida Y; Department of Internal Medicine, Liver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Root DE; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.
  • Felli E; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Pessaux P; Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, Strasbourg, France.
  • Mukherji A; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Mailly L; Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, Strasbourg, France.
  • Schuster C; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Brino L; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Nassal M; Université de Strasbourg, Inserm, Institut de Recherche sur les Maladies Virales et Hépatiques UMRS 1110, Strasbourg, France.
  • Baumert TF; IGBMC, Plateforme de Criblage Haut-débit, Illkirch, France.
Gut ; 2022 Dec 09.
Article en En | MEDLINE | ID: mdl-36591611
ABSTRACT

OBJECTIVES:

Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and hepatocellular carcinoma. A key feature of HBV replication is the synthesis of the covalently close circular (ccc)DNA, not targeted by current treatments and whose elimination would be crucial for viral cure. To date, little is known about cccDNA formation. One major challenge to address this urgent question is the absence of robust models for the study of cccDNA biology.

DESIGN:

We established a cell-based HBV cccDNA reporter assay and performed a loss-of-function screen targeting 239 genes encoding the human DNA damage response machinery.

RESULTS:

Overcoming the limitations of current models, the reporter assay enables to quantity cccDNA levels using a robust ELISA as a readout. A loss-of-function screen identified 27 candidate cccDNA host factors, including Y box binding protein 1 (YBX1), a DNA binding protein regulating transcription and translation. Validation studies in authentic infection models revealed a robust decrease in HBV cccDNA levels following silencing, providing proof-of-concept for the importance of YBX1 in the early steps of the HBV life cycle. In patients, YBX1 expression robustly correlates with both HBV load and liver disease progression.

CONCLUSION:

Our cell-based reporter assay enables the discovery of HBV cccDNA host factors including YBX1 and is suitable for the characterisation of cccDNA-related host factors, antiviral targets and compounds.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gut Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Gut Año: 2022 Tipo del documento: Article